Skip Ribbon Commands
Skip to main content
Menu

Current Clinical Trials

​For enquiries, please email clinical.trials@nccs.com.sg

Phase 1


No Site​ ​Stage of cancer Title of study ​Principal investigator ​Details of trial ​Status
1NSCLC, Melanoma, all solid tumors except CRC IV​CTNO155X2101
An Open-label, multi-center, Phase I, dose finding study of oral TNO155 in adult patients with advanced solid tumors
​Dr Daniel TanNCT03114319​Open
2
​​Lung​​LOCALLY ADVANCED/ METASTATIC - First LineCPDR001C2101
Phase 1b, multicenter, open label, 3 arm, dose de-escalation study of PDR001 in combination with platinum-doublet chemotherapy in 1st line, PD-L1 unselected, NSCLC patients
​Dr Daniel TanNCT03064854​Open
3
​​All Solid Tumour​documented RET infusionLOXO-RET-17001
A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
​Dr Daniel TanNCT03157128​Open
4
NSCLC, Pancreas and all solid tumors ​IVMCLA-128-CL01
A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
​Dr Justina Lam NCT02912949​Open
5
​NSCLC​​with documented EGFR Exon 20 insertion mutation CLN-081-001
 A Phase 1/2a, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
​Dr Daniel TanNCT04036682Open
6
​​All Solid Tumour​documented RET infusionLIBRETTO-201
A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation
​Dr Daniel TanNCT03906331Open
7
​All Solid Tumour​​​Advanced recurrentTHOR-707-101
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in a Combination Therapy in Adult Subjects with Advanced or Metastatic Solid Tumors
​Dr Tira TanNCT04009681Open
8
​All Solid Tumour​​Advanced recurrentTAPISTRY
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial
​Dr Tira TanNCT04589845Open
9
NSCLC, CRC​​Advanced recurrentCJDQ443A12101
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation
​​​Dr Daniel Tan​NCT04699188​Open
10
​NSCLC​​Advanced recurrentDESTINY-Lung03
A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)
​Dr Stephanie SawNCT04686305On hold
​11
​NSCLC​​Advanced recurrentBayer 21607
An open label, first-in-human study of BAY 2927088 in participants with advanced non-small cell lung cancer (NSCLC) harboring an EGFR and/or HER2 mutation
​Dr Daniel TanNCT05099172​Open
12
​NSCLC​​Advanced recurrentBLU-945-1101
A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung Cancer
​Dr Daniel TanNCT04862780​On hold
13
​Cholangio and all soild tumors​with FGFR2 mutationRLY-4008-101
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors Cancers
​Dr David TaiNCT04526106​Open
​14
​NSCLC
HNSCC
Urothelial
​​Advanced recurrentBAYER 21343
An open-label, Phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors
​​Dr Daniel TanNCT04999202​Open
15
​Breast and Gastric
​with HER2+
GO40311
A PHASE Ia/b, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BTRC4017A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT AND IN COMBINATION WITH TRASTUZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HER2-EXPRESSING CANCERS

​Dr Tira Tan
NCT03448042
Open
16
​NPC
​Recurrent / Metastatic
VT3996-301 
An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

​Dr Darren Lim
NCT05166577
​Open
​17
​Sarcoma (Lipo-sarcoma except ddLPS, undifferentiated pleo-mophic sarcoma, myxofibro-sarcoma, synovial sarcoma and leimyo sarcoma
​TP53 Wild type
​BI 1403-0002
A phase 1a/1b, open label, dose-escalation study of the combination of BI 907828 with BI 754091 (ezabenlimab) and BI 754111 and the combination of BI 907828 with BI 754091(ezabenlimab) followed by expansion cohorts, in patients with advanced solid tumors. 

​Dr Darren Lim
NCT03964233
​Open
​18
HCC
​Advanced recurrent
SCG 101-UR-103
A Phase I/ IIa, single arm, multicenter study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
​Dr Toh Han Chong
NCT05417932
​Open
19
​HCC (positive GPC3 expression )
Recurrent/ Metastatic
TCD17240
A Phase 1/2 open-label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR444200-based regimen in participants with advanced solid tumors
​Dr Darren Lim
NCT05450562
​Open
​20
​All solid tumours
​KRAS G12Cmut
​CJDQ443E12101
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in advanced solid tumor patients harboring the KRAS G12C mutation
​Dr Stephanie Saw
NCT05358249
​Open
21
​All solid tumours
​Prior IO responders
​BAYER 21820
First-in-human dose-escalation and expansion study of the anti-CCR8 antibody BAY 3375968 in combination with pembrolizumab to evaluate the safety, tolerability, and pharmacokinetics in participants with selected advanced solid tumors
​Dr Tira Tan
NCT05537740
​Open
​22
​NSCLC & HNSCC
​KRAS G12Cmut
​BGB-A317-A445-101
Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination with the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

​Dr Stephanie Saw
NCT04215978
​Open
​23
​HCC
​1st line HCC
​BMS CA224-106
A Phase 1/2, Safety Confirmation and Double-Blind, Randomized Study of Relatlimab in Combination with Nivolumab and Bevacizumab in Treatment-Naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106)
​Dr David Tai
NCT05337137
Open
​24
​Breast and other solid tumours (excluding CRC)
​PIK3CA H1047R mut
​LOXO-PIK-21001
A study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid 
​Dr Tira Tan
NCT05307705
​Open
​25
​All solid tumors & Stage B/C HCC​MYC oncogeneOTX-2002-101

A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor

​Dr David TaiNCT05497453​Open
​26
​All solid tumours​KRAS G12CmutRMC-6291-001
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors
​Dr Daniel TanNCT05462717​Open
​27
​NSCLC, GC/GEJ adenocarcinoma and all solid tumours​EGFR/c-MET amplificationMCLA-129-CL01
Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC
​Dr Justina LamNCT04868877​Open
​28
​NSCLC
ESCC
RCC
HNSCC (HPV +ive)
​​Advanced recurrentCQEQ278A12101
A phase I/Ib, open-label, multi-center, study of QEQ278 in patients with advanced solid tumors
​Dr Justina LamNCT05462873​Open
​29
​NSCLC, PDAC and GC
Advanced recurrent
EBC-129-01
A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours
Dr Matthew Ng
NCT05701527
Open
​30
​​All Solid Tumour
​Dose finding cohort: loss of SMARCA4

Backfill cohort: NSCLC with driver mutations in oncogenes (e.g., EGFR, MET, RET, ALK, BRAF, KRAS, ROS1, etc).

​PRT3645-01
Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants with Select Advanced or Metastatic Solid Tumors

​Dr Tira Tan
NCT05538572
​Open

31

Phase 1b (Dose Expansion): 

Cohorts 1 and 2: Patients with documented HER2 Tyrosine
Kinase Domain (TKD) mutation positive NSCLC

Cohort 3: Patients with documented HER2 Non-TKD mutation positive NSCLC
Advanced recurrent
BI 1479-0001
An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

Dr Aaron Tan
NCT04886804

Open

 

Current clinical trials by body parts

No Site​ ​Stage of cancer ​Title of study ​Principal investigator Details of trial Status
​1
​Bladder 
​Adjuvant
​BO42843
A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
​Dr Ravindran Kanesvaran
NCT04660344
​Open
2
Breast
​Mets TNBCBEXMET
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells from a Mesenchymal-Like to an Epithelial-Like Phenotype
​Dr Elaine Lim​NCT04664829​Open
3
​Breast​HER2+ AdjWO42633-Astefania:
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Atezolizumab or Placebo in Combination with Trastuzumab Emtansine as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer At Risk of Recurrence Who have Residual Tumor Present Pathologically in the Breast and/or Axillary Lymph Nodes Following Preoperative Therapy
​Dr Yap Yoon SimNCT04873362​Open
4
​Breast
​Mets TNBC
​TROPION Breast02
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

​Dr Rebecca Dent
NCT05374512
​Open
5
​Breast​Mets ER+PR+LaPemERLA
Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer with Letrozole in the Advanced setting – a Phase II Study
​Dr Yap Yoon SimNCT05286437​Open
6
​Breast​Mets ER+PR+ELEVATE
A Phase II randomized trial of Endocrine therapy Letrozole and Lenvatinib versus Fulvestrant in Metastatic Estrogen Receptor positive, HER2 negative breast cancer, who have progressed on CDK4/6 inhibitors
​Dr Elaine LimNCT05181033​Open
7
​Breast
​Mets HER2+/ PIK3CA mutant
​INAVO122:
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo versus Placebo in Combination with Phesgo after First Line Induction Therapy in Participants with PIK3CA-mutated HER2-positive Locally Advanced or Metastatic Breast Cancer
​Dr Yap Yoon Sim
NCT05894239

​Open
​8
​Breast
​Mets TNBC PDL1+
​ASCENT-04  (GS-US-592-6173)
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
​Dr Tira Tan
NCT05382286
​Open
​9
​Breast
​Mets HER2-/HR+
GS-US-598-6168/ ASCENT-07
A Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy.

​Dr Rebecca Dent
NCT05840211
​Open
10
​Colorectal
​NeoadjuvantOTSP-WoOCRC / MK-3475-886
Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer
​Dr Iain Tan NCT03984578​Open
11
​Colorectal
​ADVANCED/ METASTATIC 
​A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
​Dr Koo Si-Lin
NCT05425940
​Open
​12
​Esophageal
​Metastasis 1st line
​A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
​Dr Justina Lam
NCT04949256
​Open
13
​Gastric GEJ
​Advanced 2nd lineDS8201-A-U306
A Phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive advanced gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen
​Dr Matthew NgNCT04704934​Open
14
​Gastric GEJ
​Advanced 2nd and 3rd line
ASPEN-06
A Phase 2/3 Study of ALX148 In Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma
​Dr Matthew Ng
NCT05002127
​Open
15
​Gastric GEJ
​Advance 1st line
​FORTITIUDE-101
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab plus Chemotherapy versus Placebo plus Chemotherapy in Subjects with Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression
​Dr Matthew Ng
NCT05052801
​Open
16
​GEA
​Advance 1st line
​ZWI-ZW25-301
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
​Dr Matthew Ng
NCT05152147
​Open
17
​Gastric GEJ
​Advance 1st line
​FORTITUDE-102
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
​Dr Matthew Ng
NCT05111626
​Open
18
Liver cancer or Colorectal cancer with liver metastases​AdjuvantCA209-7R9
An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)
​Dr Koo Si LinNCT04912765​Open
19
​Liver
​Locally advanced
​AHCC09
A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II trial to Compare the Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 resin microspheres) followed by Atezolizumab plus Bevacizumab versus Selective Internal Radiation Therapy (SIRT-Y90) followed by placebo in patients with locally advanced Hepatocellular Carcinoma
​Dr Toh Han Chong
NCT05377034
​Open
20
​Liver
​Resectable HCC (high risk of recurrence)
AHCC12
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)
​Dr Toh Han ChongNCT05516628​Open
21
​Liver
​1st line advanced/ mets HCC
SIERRA
A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma 
​Dr Joycelyn Lee
NCT05883644
​Open
22
​Lung
​Locally Advanced, Unresectable, Stage III NSCLC
​BO42777 (HORIZON01)
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
​Dr Darren Lim
NCT05170204

​Open
23
​Lung
​Mets NSCLCBGB-LC-201
A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination with Investigational Agents With or Without Chemotherapy in Patients with Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
​Dr Darren LimNCT05635708​Open
​24
​Lung
​Mets NSCLC
​A Phase II, Open-label, Single-arm, Multi-centre Study to Evaluate the Safety and Efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (OSTARA)
​Dr Daniel Tan
NCT05801029
​Open
​25
Lung​​Met
FURMO 004
AN OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS
Dr Gillianne Lai
NCT05607550
​Open
​26
​Lung
​SCLC
DeLLphi-304
​A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
​Dr Amit Jain
NCT05740566
​Open
​27
​Lung
​Mets NSCLC
SOS-1 / IIT-SIN-S1-2022-001
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR mutant NSCLC
​Dr Darren Lim
NCT05773092
​Open
28
​Lung
​Met NSCLC
KontRASt-06
An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation
​​Dr Gillianne Lai



NCT05445843
​Open
29

​Lymphoma
​Relapsed/Refractory EBV+ Lymphomas VT3996-202
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Subjects with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
​Dr Nagavalli SomsundaramNCT05011058​Open
30
​Lymphoma
​Relapsed/Refractory CLL/SLL
LOXO-BTK-20022
Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)
​Dr Eileen Poon
NCT04965493
​Open
31
​Lymphoma
​Relapsed/ Refractory B-cell lymphoma
MK2140-006
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
​Dr Tan Ya Hwee
NCT05458297
​Open
32
​Lymphoma
​Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
​MK1026-008
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations
Dr Nagavalli Somasundaram
NCT05624554
​Open
33
​Head and Neck

​ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA

 

First Line

ASPEN03 - AT148003
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
​Dr Ang Mei KimNCT04675294​Open
34
​Head and Neck
​ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA

First Line

ASPEN04 - AT148004
A PHASE 2 STUDY OF ALX148 IN COMBINATION WITH PEMBROLIZUMAB AND CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
​Dr Ang Mei Kim
NCT04675333

​Open
35

​NPC​Metastatic, 3rd lineSG-AAA-II-01 / CAAA601A0SG01T
A Biomarker Enrichment Phase II study of 177Lu-DOTATATE in Metastatic Nasopharyngeal Cancer with a safety run-in
​Dr Daniel TanNCT05198479​Open
36
​Head and Neck
​ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA

First Line

BGB-HNSCC-201
A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Dr Ang Mei Kim
NCT05909904
​Open
​37
​Ovarian
​Metastatic
STRO-002-GM2:
A phase II open-label study evaluating the efficacy and safety of STRO-002 in women with advanced, relapsed platinum resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) expressing Folate Receptor alpha (FolRα)
​Dr Elaine Lim
NCT05870748
​Open
38
​Pancreas
​Metastatic, any line
LDOXIRI-PDAC-01
A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients
​Dr Joycelyn Lee
NCT05929885
​Open
39
​Prostate
​MetastaticBayer 20510:
A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH
​Dr Ng Quan SingNCT04597125​Open
​40
​Renal
​Locally advanced / metastatic - 1st line
​D5086C00001 (SAMETA)
A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study of Savolitinib plus Durvalumab versus Sunitinib and Savolitinib plus Durvalumab versus Durvalumab in Participants with MET-Driven, Unresectable and Locally Advanced, or Metastatic Papillary Renal Cell Carcinoma (PRCC)
​Dr Ravindran Kanesvaran
NCT05043090
​Open
41
​Renal
​Locally advanced / metastatic - 1st line
​XL092-304
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
​Dr Ravindran Kanesvaran
NCT05678673
​Open
​42
​Renal
Localised/ Adjuvant
​MK6482-022
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy

Dr Ravindran Kanesvaran
NCT05239728
Open


General

​No Site​ ​Stage of cancer ​Title of study ​Principal investigator ​Details of trial ​Status
​1​SOLID TUMORS ​LOCALLY ADVANCED / METASTATIC - ANY LINE CLDK378A2X01B
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored certinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib
​Dr Daniel Tan NCT02584933​Open
2
​SOLID TUMORS​​LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line OnwardsAPL10101 
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
​Dr Gillianne LaiNCT03175224​Open
3​SOLID TUMORS​​LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line OnwardsTPX-0005-01
A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)
​Dr Darren LimNCT03093116Open
4
SOLID TUMORS
(currently only HCC and gastric cohorts are opened)

Advanced curatively unresectable solid tumors failing standard therapy.

HCC: must have failed at least 1 line of standard therapy

Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment)

Other solid tumours: must have failed at least 1 line of standard therapy

NCCS-2018-Phase2-PRL3
An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours
​Dr Matthew NgNCT04118114​Open
5
​SOLID TUMORS
ADVANCED/ METASTATIC - 2nd Line
STCC-01
A phase II multi-centre study evaluating the efficacy of dacomitinib for patients with epidermal growth factor receptor (EGFR)-driven advanced solid tumours with low EGFR-AS1 lncRNA expression or other novel emerging biomarkers

Dr Daniel Tan
NCT04946968
​Open
6
​SOLID TUMORS
​ADVANCED/ METASTATIC
​Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations
​Dr Joanne Ngeow
NCT04924075
Open